



CST Bulletin - May, 2024

BC Cancer ST Program Updates for May 2024

AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer VC/Vancouver General Hospital (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- <u>For PowerPlans that are versioned</u>: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click Yes to accept the new version.
 - o **Do not** use the Copy Forward functionality to ensure that the updates apply.



IMPORTANT: Any change from the standard treatment regimen (dose modification, addition of
pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being
ordered with the new version (see additional documentation regarding versioning.



Please see this month's changes below:

PowerPlan: LYBV, LYBRENTUX, LYABVD, LYAVDBV

Cycles/PowerPlans: All associated PowerPlans


Changes:

Aligned all Pretreatment plans to include the following Labs:

- CBC and Differential
- Bilirubin Total
- Alanine Aminotransferase
- Creatinine Level
- Hepatitis B Core Antibody Total
- Hepatitis B Surface Antigen
- Hepatitis B Surface Antibody

Update yellow note in Pretreatment PowerPlans to:

- If HBsAg or HBcoreAb positive, start hepatitis B prophylaxis as per current guidelines




Aligned all Labs phases to include the following Labs and Note:

- Required CBC and Differential
- Optional Bilirubin Total, Alanine Aminotransferase, and Creatinine Level
- Yellow Note "If clinically indicated, every 3 months"
- Optional Hepatitis B Surface Antigen
- Optional HBV Viral Load







PowerPlan: LYDARCBDF

Cycles/PowerPlans: All associated PowerPlans

Changes:

In Pretreatment Plan, removed Thyroid Stimulating Hormone from Baseline Labs

In treatment plan, unchecked and moved Beta 2 Macroglobulin order to "If clinically indicated" section.





ONCP LY LYDARCBDF Cycle 1 - Cycle 1, Labs (Day 8, 15, 22, 29) (Future Pending				
S F Component	Fu *Est. 1			
Albumin Creatinine Ratio Urine				
Urine, once, Order for future visit				
If clinically indicated:				
CBC and Differential				
Blood, once, Order for future visit				
☐ Creatinine Level				
Blood, once, Order for future visit				
Sodium and Potassium Panel (Electrolytes Panel Outpat				
Blood, once, Order for future visit				
☐ 🖫 🗃 Bilirubin Total				
Blood, once, Order for future visit				
Alanine Aminotransferase				
Blood, once, Order for future visit				
Alkaline Phosphatase				
Blood, once, Order for future visit				
Glucose Random				
Blood, once, Order for future visit				
Calcium Level				
Blood, once, Order for future visit				
☐ Albumin Level				
Blood, once, Order for future visit				
☐ Protein Electrophoresis Urine				
Urine, once, Order for future visit				
☐ 🖥 📝 Immunoglobulin Panel (lgA, lgG, lgM)				
Blood, once, Order for future visit				
☐ Beta 2 Microglobulin				
Blood, once, Order for future visit				
Versioning: Yes				
Jira: CST-260058				

PowerPlan: CNBEV

Cycles/PowerPlans: All associated treatment PowerPlans


Changes:

In Pre-Chemo Metrics section:

- Updated Creatinine Clearance to 50ml/min.
- Updated Bilirubin to "Total Bilirubin".







PowerPlan: UGUNMPENZ, GUMCSPENZ, UGUPENZ, UGUPAJABI, GUMCSPABI, UGUPABI, UGUNMPDAR, GUMCSPAPA, UGUPAPA


Cycles/PowerPlans: All associated treatment PowerPlans

Changes:

For UGUNMPENZ, GUMCSPENZ, UGUPENZ:

In the Pretreatment Plan, added the following labs to Baseline Labs phase:

- Prostate Specific Antigen
- Testosterone Level




In the Treatment Plan:

- Added Testosterone Level.
- Added Follow up Clinic- Radiation Oncology Order with mutually exclusive linking to Follow up Clinic-Oncology On Treatment Order.








For UGUPAJABI, GUMCSPABI, UGUPABI:

In the Pretreatment Plan, added the following Labs to Baseline Labs Phase:

- Prostate Specific Antigen (Prechecked)
- Protein Level
- Albumin Level
- Gamma Glutamyl Transferase
- Lactate Dehydrogenase
- Thyroid Stimulating Hormone
- Calcium Level









In the Treatment Plan:

- Removed the 0.75mg option for dexamethasone prescription.
- Added 0.5mg option for dexamethasone prescription.
- Added Follow up Clinic- Radiation Oncology Order with mutually exclusive linking to Follow up Clinic-Oncology On Treatment Order.






For UGUNMPDAR:

In the Pretreatment Plan, added the following Labs to Baseline Labs phase:

- Alkaline Phosphatase
- Gamma Glutamyl Transferase
- Testosterone Level









In the Treatment Plan:

- Added Testosterone Level
- Added HbA1c
- Added Calcium Level
- Added Glucose Random
- Added Follow up Clinic- Radiation Oncology Order with mutually exclusive linking to Follow up Clinic-Oncology On Treatment Order






For GUMCSPAPA, UGUPAPA:

In the Pretreatment Plan, added the following labs to Baseline Labs phase:

Testosterone Level








In the Treatment Plan:

- Added Testosterone Level.
- Added Follow up Clinic- Radiation Oncology Order with mutually exclusive linking to Follow up Clinic-Oncology On Treatment Order.



PowerPlan: GIAVPG

Cycles/PowerPlans: All associated PowerPlans and Regimens

Changes:

Updated Regimen Description and Link to Protocol Note to: First-line Palliative Chemotherapy for Advanced Gallbladder, Pancreatic Carcinoma, and Cholangiocarcinoma using Gemcitabine and Platinum.

ONC GI GIAVPG CARBOplatin Option


First-line Palliative Chemotherapy for Advanced Gallbladder, Pancreatic Carcinoma, and Cholangiocarcinoma using Gemcitabine and Platinum






In the Pretreatment Plan:

- Added Albumin Level and Electrolytes Panel Outpatient (Na, K) to Baseline Labs phase.
- Removed INR order and PTT order.




- Added a Diagnostics Phase with an optional Electrocardiogram 12 Lead ECG.




In the Treatment Plan:

- Added Alanine Aminotransferase.
- Added Alkaline Phosphatase.
- Added Albumin Level.
- Added Electrolytes Panel Outpatient (Na, K).
- Removed INR order and PTT order.




Added a Diagnostics Phase with an optional Electrocardiogram 12 Lead ECG.







Versioning: Yes
Jira: CST-259169



PowerPlan: BRAJLHRHAI, BRAJLHRHT, BRAVLHRHAI, BRAVLHRHT, BRAVPALAI, BRAVPBFLV, BRAVPBFLV, BRAVRBFLV, BRAVRIBAI

Cycles/PowerPlans: ONCP BR BRAJLHRHAI (PO) (6 months) Cycles 2+, ONCP BR BRAJLHRHT (PO) (6 months) Cycles 2+, ONCP BR BRAVLHRHAI (PO) (6 months) Cycles 2+, ONCP BR BRAVLHRHT (PO) (6 months) Cycles 2+, ONCP BR BRAVPALAI Continuous Hormonal, ONCP BR BRAVPBFLV Continuous Hormonal (3 Months) Cycle 2, ONCP BR BRAVPBFLV Continuous Hormonal (3 Months) Cycles 3+, ONCP BR BRAVRBFLV Continuous Hormonal (3 Months) Cycles 3+, ONCP BR BRAVRBFLV Continuous Hormonal

Changes:

Removed all buserelin orders from Prescription phase and In-Clinic Injections phase.



ONCP BR BRAJLHRHAI (PO) (6 months) Cycles 2+, Prescriptions (Future Pending)			
😿 🗳 Link to Protocol: Neoadjuvant or Adjuvant Ovarian Suppression and Aromatase Inhibito			
Treatment Regimen			
Choose ONE aromatase inhibitor:			
🗆 👸 🖫 letrozole	▼ 2.5 mg, PC		
🗆 🐞 🖫 anastrozole	1 mg, PO,		
🗆 🥦 🛄 exemestane	▼ 25 mg, PO		
Choose one of the following:			
goserelin (goserelin long acting (ZOLADEX))	3.6 mg, su		
goserelin (goserelin long acting (ZOLADEX	10.8 mg, s		
leuprolide (leuprolide long acting (LUPRON	▼ Select an		
ONCP BR BRAJLHRHAI (PO) (6 months) Cycles 2+, In-Clinic Injections (Veek		
⊗ ♥ Component			
	*Est		
/8 r			
For patients who will be receiving doses in clinic			
✓ ZOLADEX every 4 weeks: ☐ So goserelin (goserelin long acting (ZOLADEX))			
S goserelin (goserelin long acting (ZOLADEX)) 3.6 mg, subcutaneous, once oncology, drug form: syringe-i			
So ring, subcutaneous, once oncology, drug forms syningers			
goserelin (goserelin long acting (ZOLADEX LA))			
10.8 mg, subcutaneous, once oncology, drug form: syringe			
S LUPRON DEPOT every 4 weeks:			
See Seleuprolide (leuprolide long acting (LUPRON DEPOT))			
7.5 mg, IM, once oncology, drug form: inj-long acting, Use			
UPRON DEPOT every 12 weeks:			
See leuprolide (leuprolide long acting (LUPRON DEPOT))			
22.5 mg, IM, once oncology, drug form: inj-long acting, Use			
A Cabadulable Onders			
Versioning: Yes			
Jira: CST-257984			

PowerPlan: UGIPRRT

Cycles/PowerPlans: Associated Treatment Plan and Regimen

Changes:


Updated Regimen Description and Link to Protocol Note to: Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium 177 Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Neuroendocrine Tumours.

In the Pre-Chemo Metrics section, updated Creatinine Clearance to 40 mL/min.



ON	ONCP GI UGIPRRT - Cycle 1, Nuclear Medicine (Day 1) (Future Pending) *Est.		
	ø,	8	Component
		寥	Link to Protocol: Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium 177 Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Neuroendocrine Tumours
	⟨♣ Revised: 1 March 2023		
			Pre-Chemo Metrics
			Neutrophils Greater Than or Equal to 1.0 x 10^9/L within 14 days
			Platelet Count Greater Than or Equal to 75 x 10^9/L within 14 days
			Creatinine Clearance Greater Than or Equal to 40 mL/min within 14 days
			/8 5 14 11 11

In the Labs Phase, moved INR order from optional to required.



Versioning: Yes

Jira: CST-255358

PowerPlan: GOOVCAG

Cycles/PowerPlans: Associated Treatment Plan

Changes:

In the Labs phase, removed Day 14 lab.





Blood, once, Order for future visit Creatinine Level Blood, once, Order for future visit Planned If clinically indicated: Cancer Antigen 19-9 Blood, once, Order for future visit Cancer Antigen 15-3 Blood, once, Order for future visit			Day 22
Test. 19-Apr-2024 08: Actions ▼	S 77 C	Future Pending	Future Pending
☐ CBC and Differential Blood, once, Order for future visit ☐ Creatinine Level Blood, once, Order for future visit ☐ Cancer Antigen 19-9 Blood, once, Order for future visit ☐ Cancer Antigen 15-3 Blood, once, Order for future visit ☐ Cancer Antigen 125	Ø Y Component	*Est. 19-Apr-2024 08:	*Est. 03-May-2024 08:
Blood, once, Order for future visit Creatinine Level Blood, once, Order for future visit Planned If clinically indicated: Cancer Antigen 19-9 Blood, once, Order for future visit Cancer Antigen 15-3 Blood, once, Order for future visit Cancer Antigen 125		Actions ▼	Actions ▼
✓ Creatinine Level Blood, once, Order for future visit Planned Fit clinically indicated: Cancer Antigen 19-9 Blood, once, Order for future visit Cancer Antigen 15-3 Blood, once, Order for future visit Cancer Antigen 125	CBC and Differential		
Blood, once, Order for future visit Planned If clinically indicated: Cancer Antigen 19-9 Blood, once, Order for future visit Cancer Antigen 15-3 Blood, once, Order for future visit Cancer Antigen 125	Blood, once, Order for future visit	Planned	Planned
☐ If clinically indicated: ☐ Cancer Antigen 19-9 Blood, once, Order for future visit ☐ Cancer Antigen 15-3 Blood, once, Order for future visit ☐ Cancer Antigen 125	✓ Creatinine Level		
Cancer Antigen 19-9 Blood, once, Order for future visit Cancer Antigen 15-3 Blood, once, Order for future visit Cancer Antigen 125	Blood, once, Order for future visit		Planned
Blood, once, Order for future visit Cancer Antigen 15-3 Blood, once, Order for future visit Cancer Antigen 125	∮ If clinically indicated:		
Cancer Antigen 15-3 Blood, once, Order for future visit Cancer Antigen 125	Cancer Antigen 19-9		
Blood, once, Order for future visit Cancer Antigen 125	Blood, once, Order for future visit		
☐ Cancer Antigen 125	Cancer Antigen 15-3		
Blood, once, Order for future visit	Cancer Antigen 125		
	Blood, once, Order for future visit		

PowerPlan: CNAJ12TZRT

Cycles/PowerPlans: Associated Powerplans and Regimens

Changes:

Regimen description and Link to Protocol note are updated to: Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation

ONC CN CNAJ12TZRT (Pending)

Hide additional details

Regimen description: Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation

Versioning: Yes

Jira: CST-262521

Jira Ticket #	CST-262521, CST-260143, CST-260058, CST-260019, CST-259169, CST-258584, CST-257984, CST-256745, CST-255681, CST-255358
How-to questions?	http://cstcernerhelp.healthcarebc.ca/
Need further support?	CST Phone Support: 1-844-214-7444



